Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis.
How do 'stimulants' reduce hyperactivity in children and adults? How can drugs which raise extracellular dopamine result in psychomotor slowing of hyperactive children when dopamine is known to enhance motor activity, such as in Parkinson's disease? In summary, the hypothesis for the anti-hyperactivity effects of the stimulants is as follows: during normal nerve activity, extracellular dopamine levels transiently rise 60-fold. At low therapeutic doses (0.2-0.5 mg/kg) to treat attention-deficit hyperactivity disorder, stimulant drugs such as methylphenidate and dextroamphetamine reduce locomotion in both humans and animals. The drugs raise resting extracellular levels of dopamine several-fold, but reduce the extent to which dopamine is released with nerve impulses, compared to the impulse-associated release in the absence of the drug. This relatively reduced amplitude of impulse-associated dopamine would result in less activation of post-synaptic dopamine receptors which drive psychomotor activity. At higher doses, stimulants produce generalized stimulation of the nervous system, as a result of the very high concentrations of extracellular dopamine at rest, and the markedly increased release of dopamine with nerve impulses. These high levels of resting and pulsatile dopamine cause widespread stimulation of post-synaptic dopamine receptors, overcoming any concomitant presynaptic inhibition of dopamine release.
Seeman
Philip
P
Department of Pharmacology, University of Toronto, Medical Science Building, Room 4344, 8 Taddle Creek Road, Ont, Canada M5S 1A8. philip.seeman@utoronto.ca
Madras
Bertha
B
D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007175:Impulsive Behavior / Q000188:drug therapy / Q000378:metabolism*; D008774:Methylphenidate / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects; D013569:Synapses / Q000187:drug effects / Q000378:metabolism
D000697:Central Nervous System Stimulants; D011954:Receptors, Dopamine; D008774:Methylphenidate; D004298:Dopamine